NAA10: A Protein with Potential as A Drug Target Or Biomarker

Target Name: NAA10

NCBI ID: G8260

NAA10

NAA10: A Protein with Potential as A Drug Target Or Biomarker

NAA10, also known as OGDPN, is a protein that is expressed in various tissues throughout the body. It is a member of the G-protein-coupled receptor (GPCR) family and is involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

Recent studies have suggested that NAA10 may have potential as a drug target or biomarker. One of the main reasons for this is its involvement in the regulation of cell survival and the ability to induce cell death in response to various stimuli. This is important because NAA10 has been shown to be involved in the development and progression of various diseases, including cancer.

In addition to its potential as a drug target, NAA10 has also been shown to be a potential biomarker for several diseases. For example, studies have shown that NAA10 levels are elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that NAA10 may be a useful biomarker for these diseases and could potentially be used for early detection and treatment.

Another potential use of NAA10 is its role in the regulation of cell adhesion and migration. This is important because NAA10 has been shown to be involved in the development and maintenance of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function.

In addition to its role in cell adhesion and migration, NAA10 has also been shown to be involved in the regulation of cell signaling pathways. This is important because NAA10 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival and is a key target for many diseases, including cancer.

Overall, NAA10 is a protein that has been shown to be involved in a wide range of cellular processes and has potential as a drug target or biomarker. Further research is needed to fully understand its role in these processes and to determine its potential as a therapeutic agent.

Protein Name: N-alpha-acetyltransferase 10, NatA Catalytic Subunit

Functions: Catalytic subunit of N-terminal acetyltransferase complexes which display alpha (N-terminal) acetyltransferase activity (PubMed:15496142, PubMed:19826488, PubMed:19420222, PubMed:20145209, PubMed:27708256, PubMed:25489052, PubMed:29754825, PubMed:20154145, PubMed:32042062). Acetylates amino termini that are devoid of initiator methionine (PubMed:19420222). The alpha (N-terminal) acetyltransferase activity may be important for vascular, hematopoietic and neuronal growth and development. Without NAA15, displays epsilon (internal) acetyltransferase activity towards HIF1A, thereby promoting its degradation (PubMed:12464182). Represses MYLK kinase activity by acetylation, and thus represses tumor cell migration (PubMed:19826488). Acetylates, and stabilizes TSC2, thereby repressing mTOR activity and suppressing cancer development (PubMed:20145209). Acetylates HSPA1A and HSPA1B at 'Lys-77' which enhances its chaperone activity and leads to preferential binding to co-chaperone HOPX (PubMed:27708256). Acetylates HIST1H4A (PubMed:29754825). Acts as a negative regulator of sister chromatid cohesion during mitosis (PubMed:27422821)

The "NAA10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NAA10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets